Profund Advisors
DNTH icon

Profund Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Profund Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.86M Buy
21,154
+2,607
+14% +$271K 0.05% 220
2026
Q2 		$1.81M Buy
18,547
+4,297
+30% +$375K 0.05% 219
2026
Q1 		$1.2M Sell
14,250
-7,090
-33% -$411K 0.04% 302
2025
Q4 		$879K Buy
+21,340
New +$827K 0.03% 380

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Peak Financial Advisors
Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
QP Wealth Management
QP Wealth Management Eatontown, New Jersey $66.5M AUM 63.94% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Profund Advisors's DNTH Position: Q3 2026 in Review

Profund Advisors increased its Dianthus Therapeutics (DNTH) stake by 14% in Q3 2026, buying an estimated $271K and bringing the position to 21,154 shares worth $1.86M. The position accounts for 0.05% of the portfolio, ranked #220.

Profund Advisors first reported a position in DNTH in Q4 2025 and has held it in 4 quarters since. 39 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Profund Advisors held 21,154 shares of Dianthus Therapeutics worth $1.86M as of Q3 2026.
  • Profund Advisors bought 2,607 Dianthus Therapeutics shares in Q3 2026, an estimated $271K.
  • Dianthus Therapeutics made up 0.05% of Profund Advisors's portfolio in Q3 2026, its #220 holding.
  • Profund Advisors first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 39 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.